Compare · ANIP vs ELOX
ANIP vs ELOX
Side-by-side comparison of ANI Pharmaceuticals Inc. (ANIP) and Eloxx Pharmaceuticals Inc. (ELOX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. ANIP focuses on Biotechnology: Pharmaceutical Preparations, while ELOX focuses on Biotechnology: Biological Products (No Diagnostic Substances).
- ANIP is the larger of the two at $1.69B, about 42.5x ELOX ($39.7M).
- ANIP has been more active in the news (8 items in the past 4 weeks vs 6 for ELOX).
- ANIP has more recent analyst coverage (11 ratings vs 4 for ELOX).
- Company
- ANI Pharmaceuticals Inc.
- Eloxx Pharmaceuticals Inc.
- Price
- $75.36+0.88%
- $3.99-4.55%
- Market cap
- $1.69B
- $39.7M
- 1M return
- -8.52%
- -
- 1Y return
- +23.78%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- News (4w)
- 8
- 6
- Recent ratings
- 11
- 4
ANI Pharmaceuticals Inc.
ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract manufacturing for other pharmaceutical companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was founded in 2001 and is headquartered in Baudette, Minnesota.
Eloxx Pharmaceuticals Inc.
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribonucleic acid modulating drug candidates for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial that focuses on the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.
Latest ANIP
- ANI Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference
- ANI Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Director Walsh Patrick D sold $1,127,120 worth of shares (13,973 units at $80.66), decreasing direct ownership by 27% to 38,432 units (SEC Form 4)
- SVP, HEAD - ESTABLISHED BRANDS Rowland Thomas Andrew sold $36,357 worth of shares (459 units at $79.21), decreasing direct ownership by 1% to 38,271 units (SEC Form 4)
- PRESIDENT & CEO Lalwani Nikhil sold $4,266,350 worth of shares (55,000 units at $77.57), decreasing direct ownership by 14% to 349,889 units (SEC Form 4)
- SVP, GENERICS Gutwerg Ori sold $220,374 worth of shares (2,772 units at $79.50), decreasing direct ownership by 3% to 78,696 units (SEC Form 4)
- SR. VP, GENERAL COUNSEL & SEC. Cook Meredith sold $39,080 worth of shares (500 units at $78.16) as part of a pre-agreed trading plan, decreasing direct ownership by 0.63% to 78,390 units (SEC Form 4)
- ANI Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form 10-Q filed by ANI Pharmaceuticals Inc.
- ANI Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
Latest ELOX
- SEC Form 8-A12B filed by Eloxx Pharmaceuticals Inc.
- Amendment: SEC Form S-1/A filed by Eloxx Pharmaceuticals Inc.
- Eloxx Pharmaceuticals Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
- SEC Form 3 filed by new insider Webster Stephen W
- SEC Form 3 filed by new insider Kjellson Nina S
- Large owner Coastlands Capital Lp disposed of 1,250,000 shares (SEC Form 4)
- Director Rubin Steven D converted options into 1,875 shares, increasing direct ownership by 15% to 14,625 units (SEC Form 4)
- President and CEO Aggarwal Sumit exercised 472,826 shares at a strike of $0.08 and was granted 1,000,000 shares, increasing direct ownership by 737% to 1,672,756 units (SEC Form 4)
- Director Walts Alan Edmund converted options into 1,875 shares, increasing direct ownership by 14% to 15,567 units (SEC Form 4)
- SEC Form DEF 14C filed by Eloxx Pharmaceuticals Inc.